Literature DB >> 32307133

Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid.

Lianne M Reus1, Sven Stringer2, Danielle Posthuma2, Charlotte E Teunissen3, Philip Scheltens4, Yolande A L Pijnenburg4, Pieter Jelle Visser5, Betty M Tijms4.   

Abstract

Genetic factors play a major role in Alzheimer's disease (AD) pathology, but biological mechanisms through which these factors contribute to AD remain elusive. Using a cerebrospinal fluid (CSF) proteomic approach, we examined associations between polygenic risk scores for AD (PGRS) and CSF proteomic profiles in 250 individuals with normal cognition, mild cognitive impairment, and AD-type dementia from the Alzheimer's Disease Neuroimaging Initiative. Out of 412 proteins, 201 were associated with PGRS. Hierarchical clustering analysis on proteins associated with PGRS at different single-nucleotide polymorphism p-value inclusion thresholds identified 3 clusters: (1) a protein cluster correlated with highly significant single-nucleotide polymorphisms, associated with amyloid-beta pathology and complement cascades; (2) a protein cluster associated with PGRS additionally including variants contributing to modest risk, involved in neural injury; (3) a protein cluster that also included less strongly associated variants, enriched with cytokine-cytokine interactions and cell adhesion molecules. These findings suggest that CSF protein levels reflect varying degrees of genetic liability for AD and may serve as a tool to investigate biological mechanisms in AD.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease (AD); Cell adhesion molecules; Cerebrospinal fluid (CSF); Complement cascades; Cytokines; Polygenic risk scores (PGRS)

Mesh:

Substances:

Year:  2020        PMID: 32307133     DOI: 10.1016/j.neurobiolaging.2020.03.012

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  6 in total

1.  Neuroprotective potential of the oxindole alkaloids isomitraphylline and mitraphylline in human neuroblastoma SH-SY5Y cells.

Authors:  Mario A Tan; Seong Soo A An
Journal:  3 Biotech       Date:  2020-11-09       Impact factor: 2.406

Review 2.  Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2021-09-28       Impact factor: 16.655

3.  APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.

Authors:  Miles Berger; Mary Cooter; Alexander S Roesler; Stacey Chung; John Park; Jennifer L Modliszewski; Keith W VanDusen; J Will Thompson; Arthur Moseley; Michael J Devinney; Shayan Smani; Ashley Hall; Victor Cai; Jeffrey N Browndyke; Michael W Lutz; David L Corcoran
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 4.  Polygenic Score Models for Alzheimer's Disease: From Research to Clinical Applications.

Authors:  Xiaopu Zhou; Yolanda Y T Li; Amy K Y Fu; Nancy Y Ip
Journal:  Front Neurosci       Date:  2021-03-29       Impact factor: 4.677

5.  Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts.

Authors:  Flora H Duits; Kirsten E J Wesenhagen; Laura Ekblad; Emma Wolters; Eline A J Willemse; Philip Scheltens; Wiesje M van der Flier; Charlotte E Teunissen; Pieter Jelle Visser; Betty M Tijms
Journal:  Alzheimers Res Ther       Date:  2021-01-04       Impact factor: 6.982

6.  Diaportheone A Analogues Instigate a Neuroprotective Effect by Protecting Neuroblastoma SH-SY5Y Cells from Oxidative Stress.

Authors:  Mario A Tan; Elena Zakharova; Seong Soo A An
Journal:  Biology (Basel)       Date:  2021-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.